UK cardiac biomarker market is estimated to grow significantly at a CAGR of around 7.7% during the forecast period. The major factor that contribute in the market growth include increasing CVDs in the country coupled with availability of advanced diagnostic technology for heart related diseases in the country. Furthermore, the nation has the highest number of CVD, Congenital heart disease (CHD), stroke, heart failure, atrial fibrillation and other heart related disease. According to one of the reports published by British Heart Foundation in 2017, more than one-fourth of the fatalities in UK are due to CVD, which is responsible for around 1.6 million fatalities each year. Moreover, growing preference towards personalized medicine further provide substantial opportunity to the market.   

The market is segmented on the basis of type, application, and location of testing. Based on type, the market is segregated into Creatine kinase (CK-MB), Troponins (T, I), Myoglobin, Natriuretic peptides (BNP & NT-PROBNP), Ischemia modified albumin and Others. The troponin is anticipated to be the fastest growing and has a considerable market share in the UK cardiac biomarker market due to easy and high sensitivity that results in the high adoption of the test. Based on Application, the market is segmented into myocardial infraction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. On the basis of the location of testing, the market is classified into laboratory testing and point of care testing.  

The companies which are contributing to the growth of UK cardiac biomarker market include Abbott Laboratories, BioMérieux S.A., Cisbio Bioassays SAS, Danaher Corp., F. Hoffmann-La Roche AG, HyTest Ltd, Merck KGaA, and others. The market players are considerably contributing to the market growth by the adoption of varioUK strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the UK cardiac biomarker market is incorporated by extensive primary and secondary research conducted by the research team.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for biotechnology companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1.  UK Cardiac biomarker Market Research and Analysis by Type
2.  UK Cardiac biomarker Market Research and Analysis by Application
3.  UK Cardiac biomarker Market Research and Analysis by Location of Testing 

The Report Covers

• Comprehensive research methodology of the UK cardiac biomarker market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the UK Cardiac biomarker market.
• Insights about market determinants which are stimulating the UK Cardiac biomarker market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.